Medtronic (NYSE:MDT) reported Q3 EPS of $1.30, $0.03 better than the analyst estimate of $1.27. Revenue for the quarter came in at $7.7 billion versus the consensus estimate of $7.54 billion.
GUIDANCE:
Medtronic raises FY2023 EPS of $5.28-$5.30, versus the prior of $5.25-$5.30 and the consensus of $5.27. The company expects fourth quarter organic revenue growth of 4.5% to 5.0%.